OBJECTIVES: This study analyzes changes in the degree of global methylationlevel in myelodysplastic syndrome during progression of the disease. METHODS: Methylation status was analyzed in 127 patients with histologically confirmed MDS and 26 reactive controls. We employed Pyrosequencing, Luminometric Methylation Assay (LUMA) and a realtime PCR-based quantitative assay. RESULTS: We detected an increase of methylation level of LINE-1 sequences using pyrosequencing and an increase of methylation in the HpaII recognition site employing LUMA during the progression of MDS. Methylation sensitive quantitative PCR showed no statistically significant differences, only a trend. CONCLUSIONS: LINE-1 and methylation sensitive cleavage of DNA can act as a surrogatmarker for global DNA methylation. The genome wide hypermethylation of MDS is a distinct feature of this disease. It discriminates MDS from other neoplasia and may explains the success of hypomethylation inducing reagents like azadeoxycytidine in MDS therapy.
OBJECTIVES: This study analyzes changes in the degree of global methylationlevel in myelodysplastic syndrome during progression of the disease. METHODS: Methylation status was analyzed in 127 patients with histologically confirmed MDS and 26 reactive controls. We employed Pyrosequencing, Luminometric Methylation Assay (LUMA) and a realtime PCR-based quantitative assay. RESULTS: We detected an increase of methylation level of LINE-1 sequences using pyrosequencing and an increase of methylation in the HpaII recognition site employing LUMA during the progression of MDS. Methylation sensitive quantitative PCR showed no statistically significant differences, only a trend. CONCLUSIONS: LINE-1 and methylation sensitive cleavage of DNA can act as a surrogatmarker for global DNA methylation. The genome wide hypermethylation of MDS is a distinct feature of this disease. It discriminates MDS from other neoplasia and may explains the success of hypomethylation inducing reagents like azadeoxycytidine in MDS therapy.
Authors: Mateusz Bujko; Ewa Musialik; Rafał Olbromski; Marta Przestrzelska; Marta Libura; Anna Pastwińska; Przemysław Juszczyński; Lech Zwierzchowski; Paweł Baranowski; Janusz Aleksander Siedlecki Journal: Int J Hematol Date: 2014-05-20 Impact factor: 2.490
Authors: Lissette Delgado-Cruzata; Hui-Chen Wu; Mary Perrin; Yuyan Liao; Maya A Kappil; Jennifer S Ferris; Julie D Flom; Hulya Yazici; Regina M Santella; Mary Beth Terry Journal: Epigenetics Date: 2012-06-18 Impact factor: 4.528
Authors: A Poloni; G Maurizi; D Mattiucci; S Amatori; B Fogliardi; B Costantini; M Mariani; S Mancini; A Olivieri; M Fanelli; P Leoni Journal: Leukemia Date: 2014-06-19 Impact factor: 11.528